Ashley Gallagher, Associate Editor

Study results show KNT-127 is a promising therapeutic option and enhances the anti-inflammatory response.

With the Delta variant, there was an increase in coronavirus-related hospitalizations by more than one-third among these individuals.

Axsome Therapeutics continues to explore its narcolepsy drug after the FDA granted it orphan drug designation.

In a Pharmacy Times® interview, Jessica Hui, a researcher and pediatric allergist at National Jewish Health, discussed how increased hand hygiene may be harming the hands of healthcare workers.

The main factors behind the vaccine hesitancy are the potential adverse effects post-vaccination and effect on their autoimmune conditions, as well as lack of trial data, an analysis shows.

The medication receives the approval after it was shown to be more effective than daily tenofovir disoproxil fumarate with emtricitabine tablets.

The agency has given the greenlight to maralixibat after the ICONIC study combined with 5 years of supportive studies that demonstrated the reduction of pruritis.

Individuals who used intranasal corticosteroids prior to being infected were about 22% less likely to be hospitalized from severe COVID-19 than those who did not.

Rivaroxaban (Xarelto, Janssen) demonstrates a lower incidence of bleeding events in pediatric patients.

T2D is associated with a higher mortality risk linked to the coronavirus than individuals with T1D.

Study shows that shedding pounds potentially decreases the risk of diabetes, dyslipidemia, and high blood pressure.

The medication has met the criteria of overall survival for individuals with this type of liver cancer who were previously treated with sorafenib, Merck says.

Patients with senile dementia who have silent epileptic activity show improvement when taking this medication.

Study results presented at an American Heart Association conference show that 34% of individuals have high blood pressure.

Investigators at Stanford Medicine find that 72% of individuals who took the highest dose of ON-SXB were considered much or very much improved.

Treatment of round pneumonia should be followed up with a 2-view chest X-ray weeks later.

An intravenous immunoglobulin option along with glucocorticoids could be effective in fighting drug-induced erythroderma for patients with AIDS.

Study shows Lefamulin, omadacycline, ceftaroline, delafloxacin are beneficial in treating community-acquired pneumonia.

The overall response rate of ruxolitinib at week 24 was 49.7% compared with 25.6% for the best available therapy treatment for graft-versus-host-disease.

It demonstrated 93.2% efficacy 14 days afterward and greater than 90% for 4 or more months.

Survey results from Kantar show that people rate these factors more important than an active family life and financial security in terms of well-being.

In clinical trials, the majority of patients with atopic dermatitis treated with ruxolitinib had clear or almost clear skin.

These patients had comparable levels of antibodies to individuals without the disease after a 2-dose course of the vaccination.

Thomas Menighan, co-founder of PursueCare and the CEO Emeritus of the American Pharmacists Association, discusses a pharmacists role in National Recovery Month.

The results of 3 phase 3 trials showed that the drug offered greater proportions of individuals with the condition who met the endpoints of clinical remission and endoscopic response.

Phase 3 trial results show that the drug reduced the risk of death or reoccurrence by 35% for individuals with high-risk disease compared with the placebo.

Nearly 94.1% of individuals treated with the drug in the DESTINY-Breast03 study were still alive at the 1-year mark, according to a statement from AstraZeneca.

Stanford research results show that of nearly 39,000 individuals, just 22 had potential allergic reactions, and all recovered.

Surgical procedures and weight-loss drugs combat high hypertension in individuals who are obese or overweight, according to the American Heart Association.

In a phase 3 trial, the medication significantly reduced the risk of disease progression compared with individuals in a placebo group.